Inhibition of brain [(3)H]cimetidine binding by improgan-like antinociceptive drugs

Eur J Pharmacol. 2010 Apr 25;632(1-3):33-8. doi: 10.1016/j.ejphar.2010.01.026. Epub 2010 Feb 6.

Abstract

[(3)H]cimetidine, a radiolabeled histamine H(2) receptor antagonist, binds with high affinity to an unknown hemoprotein in the brain which is not the histamine H(2) receptor. Improgan, a close chemical congener of cimetidine, is a highly effective pain-relieving drug following CNS administration, yet its mechanism of action remains unknown. To test the hypothesis that the [(3)H]cimetidine-binding site is the improgan antinociceptive target, improgan, cimetidine, and 8 other chemical congeners were studied as potential inhibitors of [(3)H]cimetidine binding in membrane fractions from the rat brain. All compounds produced a concentration-dependent inhibition of [(3)H]cimetidine binding over a 500-fold range of potencies (K(i) values were 14.5 to >8000nM). However, antinociceptive potencies in rats did not significantly correlate with [(3)H]cimetidine-binding affinities (r=0.018, p=0.97, n=10). These results suggest that the [(3)H]cimetidine-binding site is not the analgesic target for improgan-like drugs.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Analgesics / chemistry
  • Analgesics / pharmacology*
  • Animals
  • Binding Sites
  • Brain / metabolism*
  • Cimetidine / analogs & derivatives*
  • Cimetidine / antagonists & inhibitors*
  • Cimetidine / chemistry
  • Cimetidine / pharmacology
  • Dose-Response Relationship, Drug
  • Histamine / metabolism
  • Histamine H2 Antagonists / metabolism
  • Male
  • Molecular Structure
  • Pain / metabolism
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Analgesics
  • Histamine H2 Antagonists
  • SKF 92374
  • Cimetidine
  • Histamine